Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Jinhai Medical Technology Limited
今海醫療科技股份有限公司

(Incorporated in the Cayman Islands with members' limited liability)

(Stock Code: 2225)

VOLUNTARY ANNOUNCEMENT
STRATEGIC COOPERATION MEMORANDUM

This announcement is made by Jinhai Medical Technology Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to provide its shareholders and potential investors with the updates on the recent development of the business of the Group.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that on 2 November 2026, the Company entered into a strategic cooperation memorandum (the "**Strategic Cooperation Memorandum**") with Digital Health China Technologies Co., Ltd.（神州醫療科技股份有限公司）("**Digital Health**"), in respect of possible cooperations in areas of business operations and equity investments.

STRATEGIC COOPERATION MEMORANDUM

Principal terms of the Strategic Cooperation Memorandum are set out below:

Date: 2 November 2026

Parties: (i) the Company

(ii) Digital Health (collectively, the "**Parties**", and each a "**Party**")

Pursuant to the Strategic Cooperation Memorandum, the Parties intend to carry out in-depth explorations regarding strategic cooperations in areas of business operations and equity investments, and establish a mutually beneficial cooperation relationship by leveraging each Party's comparative advantages in resources, technologies, marketing and management. The Parties plan to explore the opportunities in merger and acquisitions of potential business projects at the business operations level and equity investments at the equity level.

Subject to compliance with applicable laws, regulations, and the internal management policies of both Parties, the Parties shall engage in further discussions regarding the aforementioned proposed matters. The specific terms of cooperation, implementation methods, project schedules, and the respective rights and obligations of the Parties shall be governed by formal agreements (if any) to be negotiated and entered into by the Parties. Hence, the transactions contemplated under the Strategic Cooperation Memorandum may or may not proceed subject to further negotiations, discussions between the Parties, and necessary due diligence and internal decision-making procedure to be completed by the Parties.

During the period from the date of the Strategic Cooperation Memorandum to 31 March 2027, the Company shall have the exclusive right to negotiate and consummate the subject matters contemplated under the Strategic Cooperation Memorandum with Digital Health.

INFORMATION OF DIGITAL HEALTH

Digital Health is a joint stock limited company established in the People's Republic of China and is principally engaged in medical big data and artificial intelligence in the medical industry.

To the best of the Directors' knowledge, information and belief and having made all reasonable enquiries, Digital Health is an independent third party independent of the Company and its connected persons (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**")).

INFORMATION OF THE GROUP

The Company is incorporated in Cayman Islands with limited liability and its shares are listed on the Main Board of the Stock Exchange. The Company is an investment holding company and the principal activities of the Group are provision of minimally invasive surgery solution and medical products and related services, manpower outsourcing and ancillary services, and dormitory services.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Jinhai Medical Technology Limited
Chen Guobao
Chairman of the Board and executive Director

Hong Kong, 2 November 2026

As at the date of this announcement, the Board comprises seven Directors, of which three are executive Directors, namely Mr. Chen Guobao, Mr. Li Bin, and Mr. Wang Zhenfei; one is non-executive Director, namely Mr. Wang Huasheng; and three are independent non-executive Directors, namely Mr. Yan Jianjun, Mr. Fan Yimin, and Ms. Liu Jinjing.